8-K Announcements
6Material company update
Jul 7, 2025·SEC
Material company update
Apr 17, 2025·SEC
Material company update
Apr 11, 2025·SEC
Vincerx Pharma, Inc.(VINC)Earnings, Financials & Key Ratios
VINC•NASDAQ
$0.01
Price updated Jun 25, 2026
AboutVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.Show more
- Revenue$0
- EBITDA-$31M+24.5%
- Net Income-$30M+25.1%
- EPS (Diluted)-5.75+15.9%
- ROE-431.29%-216.2%
VINC Price & Volume
Vincerx Pharma, Inc. (VINC) stock price & volume — 10-year historical chart
Loading chart...
Clinical Stage Pipeline Faces Critical Liquidity Constraints
Investment Thesis • Updated 2025Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity depletion risk
Key Thesis Takeaways
- Vincerx Pharma remains a high-risk, pre-revenue biotechnology entity characterized by a persistent reliance on external financing to sustain its clinical-stage research programs.
- The company's financial trajectory is defined by significant operating losses and a rapidly depleting asset base, which has fallen from $59.3 million in 2022Q4 to $4.7 million as of 2025Q1.
- Investors should exercise extreme caution as the firm's lack of tangible assets and recurring cash burn necessitate potential future dilution to maintain operational continuity.
Verdict Logic
the company's precarious liquidity position, highlighted by a cash balance of only $4.4 million against historical quarterly burn rates, suggests an imminent risk of significant shareholder dilution.
VINC Growth Metrics
Vincerx Pharma, Inc. (VINC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-18.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM40.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM123.29%
Return on Capital
10 Years-163.41%
5 Years-163.41%
3 Years-211.82%
Last Year-410.32%
Peers Comparison
Key metrics vs top competitors for Vincerx Pharma, Inc. (VINC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $66.47K | -0.00 | — | — | -431.29% | — | |
| $36.20 | $2.15B | -5.08 | 48.03% | -639.84% | -34.11% | — | |
| $116.46 | $9.51B | -31.56 | -16.72% | -612.17% | -25.02% | — | |
| $327.99 | $9.47B | -24.33 | -100% | — | -43.02% | — | |
| $38.24 | $7.85B | -13.81 | — | — | -68.16% | — | |
| $53.63 | $8.21B | 19.36 | 87.32% | 65.95% | 87.36% | — |
Compare VINC vs Peers
Vincerx Pharma, Inc. (VINC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VINC SEC Filings & Documents
Vincerx Pharma, Inc. (VINC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VINC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VINC Frequently Asked Questions
Vincerx Pharma, Inc. (VINC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Vincerx Pharma, Inc.'s revenue?
Vincerx Pharma, Inc. (VINC) reported $1.1M in revenue for fiscal year 2024.
Is VINC profitable?
Vincerx Pharma, Inc. (VINC) reported a net loss of $22.6M for fiscal year 2024.
Dividend & Returns
What is VINC's return on equity?
Vincerx Pharma, Inc. (VINC) has a return on equity (ROE) of -431.3%. Negative ROE indicates the company is unprofitable.
What is Vincerx Pharma, Inc.'s free cash flow?
Vincerx Pharma, Inc. (VINC) had negative free cash flow of $22.8M in fiscal year 2024, likely due to heavy capital investments.